Unveiling 7 Analyst Insights On Glaukos

Analysts' ratings for Glaukos GKOS over the last quarter vary from bullish to bearish, as provided by 7 analysts.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

Analysts have recently evaluated Glaukos and provided 12-month price targets. The average target is $80.86, accompanied by a high estimate of $91.00 and a low estimate of $65.00. Marking an increase of 7.46%, the current average surpasses the previous average price target of $75.25.

Analyzing Analyst Ratings: A Detailed Breakdown

A comprehensive examination of how financial experts perceive Glaukos is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Glaukos. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Glaukos compared to the broader market.
• Price Targets: Delving into movements, analysts provide estimates for the future value of Glaukos's stock. This analysis reveals shifts in analysts' expectations over time.

To gain a panoramic view of Glaukos's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on Glaukos analyst ratings.

Delving into Glaukos's Background

Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.

Glaukos: Delving into Financials

Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.

Revenue Growth: Over the 3 months period, Glaukos showcased positive performance, achieving a revenue growth rate of 9.51% as of 30 September, 2023. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Glaukos's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -39.01%, the company may face hurdles in effective cost management.

Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -6.3%, the company may need to address challenges in generating satisfactory returns for shareholders.

Return on Assets (ROA): Glaukos's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -3.2%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: Glaukos's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.8.

Understanding the Relevance of Analyst Ratings

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.